DE Burlo Group Inc. Cuts Stock Holdings in Danaher Co. (NYSE:DHR)

DE Burlo Group Inc. lowered its position in Danaher Co. (NYSE:DHR) by 4.6% in the fourth quarter, Holdings Channel.com reports. The firm owned 22,557 shares of the conglomerate’s stock after selling 1,100 shares during the quarter. DE Burlo Group Inc.’s holdings in Danaher were worth $5,178,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in DHR. Heck Capital Advisors LLC purchased a new position in shares of Danaher in the 4th quarter valued at about $27,000. Decker Retirement Planning Inc. acquired a new position in Danaher during the fourth quarter worth about $31,000. Golden State Wealth Management LLC purchased a new position in Danaher in the fourth quarter valued at about $31,000. Strategic Financial Concepts LLC acquired a new stake in shares of Danaher during the 4th quarter valued at approximately $31,000. Finally, Pineridge Advisors LLC boosted its stake in shares of Danaher by 63.3% during the 4th quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock worth $34,000 after acquiring an additional 57 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Activity at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 11.10% of the stock is owned by insiders.

Danaher Stock Up 0.4 %

DHR opened at $197.37 on Friday. Danaher Co. has a 12 month low of $171.00 and a 12 month high of $281.70. The business has a 50-day moving average of $200.87 and a two-hundred day moving average of $224.58. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The stock has a market capitalization of $141.06 billion, a price-to-earnings ratio of 37.38, a price-to-earnings-growth ratio of 2.66 and a beta of 0.86.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.26. The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.58 billion. Danaher had a net margin of 16.33% and a return on equity of 10.82%. On average, research analysts expect that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, April 25th. Investors of record on Friday, March 28th were given a $0.32 dividend. This is a positive change from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 annualized dividend and a dividend yield of 0.65%. The ex-dividend date was Friday, March 28th. Danaher’s dividend payout ratio (DPR) is 24.85%.

Analysts Set New Price Targets

DHR has been the subject of several research reports. Barclays lifted their price objective on Danaher from $205.00 to $215.00 and gave the stock an “overweight” rating in a report on Tuesday. The Goldman Sachs Group cut their price target on Danaher from $260.00 to $240.00 and set a “neutral” rating for the company in a research note on Wednesday. Guggenheim reissued a “buy” rating and issued a $250.00 price objective on shares of Danaher in a research note on Wednesday. Citigroup restated a “buy” rating on shares of Danaher in a research report on Monday, April 7th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $250.00 price target on shares of Danaher in a report on Wednesday. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $264.40.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.